Neurofilament light chain levels indicate acute axonal damage under bortezomib treatment

INTRODUCTION: Bortezomib (BTZ) is a selective and reversible proteasome inhibitor and first line treatment for multiple myeloma (MM). One of the side effects is BTZ-induced peripheral neuropathy (BIPN). Until now there is no biomarker which can predict this side effect and its severity. Neurofilamen...

Descripción completa

Detalles Bibliográficos
Autores principales: Cebulla, Nadine, Schirmer, Daniel, Runau, Eva, Flamm, Leon, Gommersbach, Sonja, Stengel, Helena, Zhou, Xiang, Einsele, Hermann, Reinhold, Ann-Kristin, Rogalla von Bieberstein, Bruno, Zeller, Daniel, Rittner, Heike, Kortüm, K. Martin, Sommer, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188420/
https://www.ncbi.nlm.nih.gov/pubmed/36802032
http://dx.doi.org/10.1007/s00415-023-11624-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188420/
https://www.ncbi.nlm.nih.gov/pubmed/36802032
http://dx.doi.org/10.1007/s00415-023-11624-2

Ejemplares similares